Pooled-analysis of prospective observational studies evaluated the efficacy and safety of bevacizumab(BEV) and paclitaxel(PTX) as the first-line chemotherapy for HER2-negative metastatic breast cancer(MBC).

Pooled-analysis of prospective observational studies evaluated the efficacy and safety of bevacizumab(BEV) and paclitaxel(PTX) as the first-line chemotherapy for HER2-negative metastatic breast cancer(MBC). - Pooled analysis of prospective bevacizumab observational studies for metastatic breast cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047290

Enrollment

2500

Registered

2022-03-26

Start date

2012-11-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Key inclusion criteria in each study (B-SHARE,ML21165,AVAREG,AVANTI)

Exclusion criteria

Exclusion criteria: Key exclusion criteria in each study (B-SHARE,ML21165,AVAREG,AVANTI)

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Progression free survival Objective response rate Time to treatment failure OS and PFS stratified by the prognostic factor index safety	—

Countries

Japan,Europe

Contacts

Public ContactMichiro Soma

Japan Breast Cancer Research Group Management Department

souma@jbcrg.jp03-6264-8873

Outcome results